Dr. Susan Logue of the Apoptosis Research Centre has received a prestigious SFI Starting Investigator Research Grant (SIRG) to identify new therapeutic targets for the treatment of triple negative breast cancer (TNBC). The SFI SIRG award supports excellent postdoctoral researchers in taking the initial steps towards a fully independent research career.

Dr. Logue will lead a 4-year research program examining the role of a protein, IRE1α, in the progression of TNBC. Unlike other forms of breast cancer no selective therapy is available for TNBC. Currently there is an urgent need to identify new targets to treat this disease. Dr. Logue’s work will examine the influence of IRE1 signaling in TNBC and specifically how it impacts on the release of cancer cell secreted signals (cancer secretome). The cancer secretome influences diverse aspects of tumour biology including growth, composition of the tumour microenvironment and therapy-induced resistance. Secretome components have become attractive therapeutic targets to either limit cancer progression or enhance the effectiveness of chemotherapy.

Dr. Logue’s work will enhance our understanding of IRE1 biology in cancer and its potential as a novel therapeutic target for the treatment of TNBC.